相关实验视频

Updated: Jun 10, 2025

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

在非小细胞肺癌中LOXL2表达与免疫疗法的相关性

Haoyan Chen¹, Lele Liu¹, Mingjiong Zhang¹

¹Department of Geriatrics, Key Laboratory of Geriatrics of Jiangsu Province, The First Affiliated Hospital of Nanjing Medical University 300 Guangzhou Road, Nanjing 210029, Jiangsu, China.

International journal of clinical and experimental pathology

|October 14, 2024

概括

类似于lysyl氧化酶2 (LOXL2) 基因表达与非小细胞肺癌 (NSCLC) 的进展和免疫细胞透有关. LOXL2可以作为预后标记物和NSCLC免疫治疗的新目标.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
遗传学遗传学是一个

背景情况:

非小细胞肺癌 (NSCLC),包括肺状细胞癌 (LUSC) 和肺腺癌 (LUAD),是全球癌症死亡的主要原因.
化疗耐药性仍然是NSCLC治疗中的重大临床挑战.
免疫疗法为NSCLC提供了一个有希望的治疗策略.

研究的目的:

为了研究基氧化酶样2 (LOXL2) 基因与NSCLC.之间的关联.
在LUAD和LUSC中探索瘤免疫微环境.
在NSCLC中识别潜在的预后生物标志物和免疫治疗点.

主要方法:

对TCGA数据集进行生物信息学分析,包括ImmuneScore,StromalScore和TumorPurity.
来自Xena数据库的22个免疫细胞透和LOXL2相关基因表达的分析.
生存曲线分析,基因本体学 (GO),基因和基因组京都百科全书 (KEGG) 路径丰富,以及RT-qPCR检测LOXL2表达.

主要成果:

LOXL2表达与NSCLC的进展有关,并且与T淋巴细胞亚群和T调节细胞密切相关.
鉴定出SEMA7A和VEGFC是与LOXL2.2相互作用的基因.
这些相互作用的基因显示出对NSCLC患者的预后特征基因的潜力.

结论:

在LUAD和LUSC的进展中,LOXL2发挥着作用.
LOXL2与瘤微环境中的特定免疫细胞群相关.
与SEMA7A和VEGFC一起,LOXL2可以作为NSCLC免疫治疗的预后标记和潜在标.

关键词:

在LOXL2中使用LOXL2.在NSCLCLC中,我们可以看到NSCLCLC.生物信息学是一种生物信息学.德克索鲁比辛 (doxorubicin) 是一种药物.免疫透免疫透是什么?

更多相关视频

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

相关概念视频

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.